Naturally derived oncolytic peptides: from discovery to clinical translation.
Oncolytic peptides are stepping up as serious contenders in cancer research. A new review dives into naturally derived oncolytic peptides (NDOPs) and their journey from discovery to clinical trials. These peptides aren’t just lab curiosities — they’re showing real promise for targeting cancer in ways traditional therapies can’t.
Chin J Nat Med
by Zhang J, Chen Y, Lu S et al.
“Naturally derived oncolytic peptides: from discovery to clinical translation. Zhang J(1), Chen Y(2), Lu S(3), Zhang X(3), Yang G(3), Zhang Z(4), Wu Y(5), Zhang X(6), Zhang W(7). Author information: (1)School of Pharmaceutical Sciences, Fudan University, Shanghai 201203, China. (2)State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guiyang 561113, China. (3)State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center for Chinese Medicine Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research and Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China. (4)Shanghai Putuo District Central Hospital Collaborative Research Center for Translational Medicine, East China Normal University, Shanghai 200062, China. (5)State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center for Chinese Medicine Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research and Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China. Electronic address: wuye@shutcm.edu.cn. (6)School of Pharmaceutical Sciences, Fudan University, Shanghai 201203, China; Shanghai Putuo District Central Hospital Collaborative Research Center for Translational Medicine, East China Normal University, Shanghai 200062, China. Electronic address: xuemzhang@fudan.edu.cn. (7)School of Pharmacy, Naval Medical University, Shanghai 200433, China. Electronic address: wdzhangy@hotmail.com. Oncolytic peptides have emerged as a distinct class of antitumor agents with the potential to overcome therapeutic resistance and enhance anticancer immunity. Most oncolytic peptides are naturally derived or structurally inspired by natural peptides, and typically display cationic and amphipathic features. Mechanistically, these physicochemical properties enable preferential binding to the negatively charged membranes of cancer cells and subsequent membrane disruption. Beyond direct membrane lysis, many naturally derived oncolytic peptides (NDOPs) perturb intracellular organelle membranes, trigger immunogenic cell death, and modulate immune cells and immune checkpoints, thereby amplifying the cancer-immunity cycle. Through these multifaceted mechanisms, NDOPs show a low tendency to induce drug resistance and can enhance response rates when combined with conventional therapies. Notably, four NDOP-based agents have advanced into clinical trials, underscoring their translational promise. In this review, we summarize the sources, structural features, and mechanisms of NDOPs, highlight innovative therapeutic applications and rational combination strategies, and further discuss the current clinical progress. We also outline key challenges and future directions for the development of NDOPs as next-generation anticancer therapeutics. Copyright © 2026 China Pharmaceutical University. Published by Elsevier B.V. All rights reserved.”
What makes NDOPs stand out? Their structure. Most are cationic and amphipathic, which lets them zero in on the negatively charged membranes of cancer cells. Once they lock on, they disrupt those membranes directly. But the story doesn’t stop at cell lysis. NDOPs can go deeper:
Disrupt organelle membranes inside cells
Trigger immunogenic cell death, ramping up the body’s immune response
Modulate immune cells and even immune checkpoints, making other therapies work better
Here’s why this matters: NDOPs don’t just kill tumor cells. They help the immune system see the cancer as a target. This dual action means less drug resistance and stronger synergy with standard treatments.
Four NDOP-based agents are already in clinical trials. That’s not vaporware — that’s tangible progress. The review also points to future directions: designing smarter peptides, optimizing combinations, and handling manufacturing hurdles.
Key takeaway: NDOPs are giving cancer researchers new weapons and new strategies. For anyone following or working in peptide research, this is a space to watch.
Looking to source or study these compounds? Check out the vendor directory for up-to-date options. NDOPs are more than a trend — they’re pushing cancer research into new territory.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.